Radionuclide antibody coupling
AssigneeNeoRx Corporation
InventorsJohn M. Reno, Becky J. Bottino
Life of this patent
Estimating the term…
Loading patent…
AssigneeNeoRx Corporation
InventorsJohn M. Reno, Becky J. Bottino
Estimating the term…
Metal radionuclide labeled proteinaceous substances which contain, in their native states, disulfide (cysteine) linkages, which find use in diagnosis and treatment of a variety of pathologic conditions. The radionuclide labeled proteinaceous substances of the present invention are formed by the treatment of the proteinaceous substance of interest with a disulfide reducing agent, followed by reaction of the reduced proteinaceous substance ("H-treated product") with a suitable radionuclide species containing, for example, .sup.99m Tc, .sup.186 Re and .sup.188 Re, or .sup.67 Cu. It has been found that the H-treated products, e.g., antibodies, react specifically with radionuclide species to form stable radionuclide labeled antibodies or other radiolabeled products. The H-treated products may be stabilized or modified in a variety of ways prior to and subsequent to complexation with the metal radionuclide.
A method of preparing a metal radionuclide-labeled protein from a protein precursor having at least oe disulfide linkage, the method comprising:
The method of claim1 wherein the reducing agent is dithiothreitol.
A method of preparing a metal radionuclide-labeled protein from a protein precursor having at least one disulfide linkage, the method comprising:
A method of preparing a storage-stable metal radionuclide complexing protein comprising
A method for direct technetium-99m labeling of a disulfide-containing protein, comprising:
A method for directly labeling a storage-stable dimercaptoprotein with a metal radionuclide, comprising:
Dependencies are inferred from the claim text.